Enjoy complimentary customisation on priority with our Enterprise License!
The migraine drugs market size is forecast to increase by USD 1.34 billion at a CAGR of 6.36% between 2023 and 2028. The market is experiencing significant growth due to the increasing number of patients diagnosed with migraines. According to the American Migraine Foundation, approximately 39 million Americans are affected by migraines. The market is driven by advancements in migraine treatments, including triptans, oral preventive treatments such as antidepressants, anti-epileptics, and beta blockers. However, concerns related to the side effects of these drugs are hindering market growth. Triptans, for instance, can cause side effects like dizziness, nausea, and muscle weakness. Oral preventive treatments, while effective, can have long-term side effects like weight gain and sexual dysfunction. As a result, pharmaceutical companies are investing in research and development to create more effective and less side-effect-prone migraine drugs.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.